Slider

Erinha ADVANCE

Breadcrumb other pages

ABOUT ERINHA-ADVANCE

  • Overview

With the support of previous H2020-funded projects, the ERINHA Research Infrastructure was successfully set up and has now entered into its operational phase. ERINHA-Advance is a H2020-funded project which aims to continue supporting the successful operation of the ERINHA Research Infrastructure to ensure its long-term sustainability. To this end, the project focuses on a number of priorities:

  • increase the number of members’ of ERINHA and thus the research capacities offered to potential users;
  • reinforce ERINHA’s European and International cooperation with relevant countries, initiatives and networks;
  • improve users’ services by testing the operability of the infrastructure through pilot activities;
  • stimulate the innovation potential of ERINHA through collaboration endeavours with industry;
  • strengthen the service provision framework with data management and data-sharing rules, clarification of IPR regimes and a solid quality assurance system for the RI and its national nodes;
  • reinforce ERINHA’s capacities through training activities;
  • communicate broadly on ERINHA’s services;
  • ensure compliance with the ethics requirements.

 

The project started on the 1st of January 2019 and will run until the 31st of December 2021.

Coordinated by ERINHA AISBL (Belgium) with the support of Inserm Transfert (France), the consortium brings together 11 partners from 8 European countries (Belgium, France, Portugal, Sweden, Hungary, Italy, Austria and Germany). 5 of these 8 European countries possess national BSL4 facilities (Inserm France, FoHM Sweden, NPHC Hungary, INMI Italy, BNI Germany), 4 of them (KUL Belgium, INSA Portugal, KI Sweden, MUG Austria) have complementary facilities essential for a research infrastructure dedicated to the study of high-consequence pathogens of Risk Group 4 (RG4). 4 of the 5 ERINHA AISBL members belong to the ERINHA-Advance consortium (Inserm, INSA, FoHM and NPHC).

Partners

The project is coordinated by Hervé Raoul, Director General of the ERINHA RI with the support of the infrastructure’s Central Coordinating Unit (CCU) and Inserm Transfert which forms the Project Management Team.

Hervé Raoul, Director General of ERINHA & coordinator of ERINHA-Advance.

The Executive Committee, composed of the WorkPackage leaders, ensures that the project runs smoothly from a technical point of view and submits any important decisions to the Governing Board for approval when necessary. The Governing Board is made up of one representative from each consortium member.


ERINHA-Advance advisory boards

The boards set up by the ERINHA Research Infrastructure will also advise ERINHA-Advance on the project progress: an Independent Advisory Board and a Board of Industrial Representatives.

The ERINHA-Advance project is organized into 7 Workpackages – working groups dedicated to a specific set of activities.  

WP1 (ERINHA/IT) aims to manage the project, including communication with the European Commission, financial management, preparation of periodic progress and financial reports.

WP2 (ERINHA/NKK) aims to increase the membership of the Research Infrastructure within the EU and to further develop international links outside Europe in order to reinforce the sustainability of ERINHA and increase Europe’s preparedness level if faced with an epidemic involving RG4 or unknown pathogens.

WP3 (INSERM/FoHM) aims to improve ERINHA AISBL users’ services through the implementation of excellence-driven pilot calls for access to ERINHA facilities. Two programmes will be developed: one on the development of innovative animal models for highly infectious agents and another on an innovative therapeutic approach for RG4 pathogens. The success of this WP will feed into WP2 and WP4.

WP4 (FoHM/ERINHA) aims to stimulate and promote the use of ERINHA services by industrial partners and SMEs in order to facilitate the interaction with European industrial and commercial partners and to identify the opportunities of co-innovation for developing equipment/technologies for ERINHA member facilities.

WP5 (ERINHA/INSA) aims to ensure the sustainability and effectiveness of high quality ERINHA services provided to private and public entities by implementing a quality management system, an effective IPR and ethical framework and a comprehensive data management and policy plan. The success of this WP will contribute to WP2, WP3 and WP4.

WP6 (ERINHA/NKK) aims to reinforce the capacity building of the Human Resources of ERINHA, and to communicate and disseminate the progress and results of all WPs.

WP7 aims to ensure compliance with the ethics requirements set out for this WP.

ERINHA-Advance TransNational Access (TNA) Programme Call for Proposals

SPECIAL SARS-CoV-2/Covid-19 CALL TO ACCESS ERINHA FACILITIES

The current pandemic of COVID-19 is unprecedented in modern times, and has caused a global crisis with considerable health, economic and social consequences. With no approved medical countermeasures available to fight SARS CoV 2, it has also ignited a major scientific momentum to better understand this new virus, limit its spread and eventually stop the pandemic.
ERINHA – the European Research Infrastructure on Highly pathogenic Agents – and its Members have come forward in this time of emergency and taken part in multiple European projects and initiatives to advance COVID-19 / SARS-CoV-2 research and accelerate the development of therapeutic and prophylactic solutions against the virus.
However, ERINHA was not only created to lead excellence driven research but also to benefit the whole scientific community. One of the most important missions of the infrastructure is to give academia and industry the opportunity to access Europe’s top high containment research facilities to develop medical countermeasures against highly pathogenic viruses.
Therefore, we now want to extend our commitment to the current scientific effort by launching a call for proposals fully dedicated to COVID-19 / SARS-CoV-2 research. With the support of the EU funded H2020 project ERINHA-Advance, we will be offering the selected scientists and their projects free of charge* transnational access (TNA) to our cutting edge high containment facilities. * Free of charge transnational access includes administrative & logistical support, free use of the installations, in accordance with all applicable national laws, local safety and health regulations, and technical & scientific support. The User Group will be in charge of procuring consumables & animals (when applicable). Routine consumables may be covered to some extent. These aspects will be discussed during project implementation.
Please note that due to all current travel restrictions, we will not be able to offer training or in person access in the frame of this call.
The selection of the projects will be based on peer review & scientific merit through fast track evaluation. In addition to scientific excellence, priority will be given to:  
  • User-Group Leaders affiliated to public institutions or private companies located in the European Union or an associated country. Note: TNA can be granted to Users based outside the EU or its associated countries but cannot represent more than 20% of the total access that will be provided under this call.
  • Proposals that clearly demonstrate the potential impact of the research on health with regards to the current COVID-19 pandemic
  • Proposals aiming at providing the research community with efficient and optimal tools for the study of SARS CoV 2
  • Proposalsaiming at developing pan anti coronavirus medical countermeasures or tools
In addition, applications must fall into one of the following scientific sections listed below. Applications that require both in vitro and in vivo work are welcome.

SECTION 1: Diagnosis tools & Immunological Tests for COVID-19 / SARS-CoV-2

Proposals in this Section may include:
  • Development of innovative technologies for COVID-19 diagnosis
  • Development of serological tests
  • Development of innovative alternatives for antibodies production for COVID-19 diagnosis purposes
  • Any other topic related to this Section

SECTION 2: Therapeutics against COVID-19 / SARS-CoV-2

Proposals in this Section may include:
  • Development of innovative COVID-19 therapeutic tools
  • Development of innovative alternatives for antibodies production for COVID-19 therapeutic purposes
  • Drug repurposing
    • In vivo anti COVID-19 / SARS-CoV-2 efficacy of known drugs
    • In vitro anti COVID-19 / SARS CoV 2 efficacy of known drugs, including high throughput SARS-CoV-2 antiviral or therapeutic screening assays
  • Drug development
    • In vivo anti COVID-19 / SARS-CoV-2 efficacy of newly developed drugs
    • In vitro anti COVID-19 / SARS-CoV-2 efficacy of newly developed drugs, including high throughput SARS-CoV-2 antiviral or therapeutic screening assays
  • Any other topic related to this Section

SECTION 3: Vaccine against SARS-CoV-2

Proposals in this Section may include:
  • Development of a vaccine against SARS-CoV-2
  • Development of new methods to improve immunogenicity of anti SARS CoV 2 vaccines
  • Any other topic related to this Section

SECTION 4: Process development

Proposals in this Section may include any COVID-19 / SARS-CoV-2 related project progressing into GMP production and aiming to set standard operating procedures for production of plasmids, cells, gene modified cells, or viruses; etc.

SECTION 5: Other Tools & Methods related to COVID-19 / SARS-CoV-2

Proposals in this Section may include:
  • Development & optimization of alternative technologies to animal models for the study of COVID-19 and/or SARS-CoV-2
  • Development of new decontamination procedures against SARS-CoV-2
  • Any other topic related to this Section
For more information about our TNA Programme, including the conditions for access & eligibility, and the selection process, please read our TNA Guidelines. For any question, please contact our staff at the Central Coordinating Unit (contact@erinha.eu). To apply, please download the ERINHA-Advance TNA Programme Guidelines, the Application Form and the Data Protection Policy (one form must be signed by each User listed in a User Group). Please make sure that you accurately describe the methodology related to your Project. This is crucial for us to estimate that we have appropriate capacities to conduct the work. Your Proposal may otherwise not pass the Feasibility Assessment. An organization can submit several applications.

IMPORTANT DATES

Opening of the call: Monday 25 May 2020
Submission deadline: Proposals are recommended to be submitted prior to Monday 22 June for priority access. Proposals received after 22 June will be evaluated, selected and implemented on a rolling basis until TNA budget is consumed. PREVIOUS CALL

Sign up to receive the ERINHA newsletter:

ERINHA-Advance annual meeting 26-27 February 2020

The 1st annual meeting will take place in Lisbon, Portugal on the 4-5 February 2020. Hosted by consortium partner INSA.

ERINHA-Advance 3rd ExCom 10-11 October 2019

The 3rd ERINHA-Advance Executive Committee meeting was held in Paris at ERINHA and Inserm’s headquarters on the 10-11 October 2019. The meeting was an opportunity to review the progress of the project since its beginning and receive comments from the Independent Advisory Board.

ERINHA-Advance Kick-off meeting

The kick-off meeting of the ERINHA-Advance project was held in Paris on the 12-13 February 2019. All members of the consortium were present. The project Executive Committee also convened for its first meeting at the same time.

Below you’ll find a list of ERINHA’s main publications, communication tools and all public deliverables produced in the framework of the project:

ERINHA RESEARCH PORTFOLIO

ERINHA has developed its scientific strategy – a Research Portfolio, which is an evolving strategy with systematic updates to match with European and Global Research and Innovation and Public Health needs. It presents ERINHA’s prioritized pathogens, built on the WHO R&D Blueprint.

ERINHA FLYER

The ERINHA Research Infrastructure at a glance

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824061.